PFE — Pfizer Inc.

Pfizer Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenues: $14.5 billion, exceeding expectations, with a 2% operational increase. Excluding COVID products, underlying growth was approximately 7%.
• Adjusted Diluted EPS: $0.75, also above expectations; reported diluted EPS was $0.47.
• Launch and Acquired Products: Generated $3.1 billion in revenue, reflecting a 22% operational growth.
• Adjusted Gross Margin: Approximately 76%, impacted by higher accrued royalty expenses.
• Operating Cash Flow: $2.6 billion; leverage ratio at approximately 2.8x.
• Capital Returned to Shareholders: $2.4 billion via dividends.

2. Strategic Updates and Business Highlights

• Pfizer reported strong progress in R&D, with three positive Phase III readouts and plans for approximately 20 pivotal study starts in 2026.
• Significant legal developments, including settlements related to Vyndamax patents, are expected to enhance growth post-2028, projecting a high single-digit revenue CAGR starting in 2029.
• The oncology segment showed robust growth, particularly from Seagen products, which grew 20% year-over-year.
• Advancements in obesity therapies, with a focus on Metsera, targeting ten Phase III studies this year.
• Continued investment in AI to enhance drug discovery and development processes.

3. Forward Guidance and Outlook

• Full Year 2026 Guidance: Revenues expected between $59.5 billion and $62.5 billion; adjusted diluted EPS projected between $2.80 and $3.00.
• The company aims to maintain and grow dividends while managing upcoming loss of exclusivity (LOE) challenges.
• Pfizer anticipates strong contributions from its product portfolio, particularly in oncology and obesity, to offset LOE impacts.

4. Bad News, Challenges, or Points of Concern

• COVID Product Declines: Sustained low disease levels are expected to continue impacting Paxlovid utilization, with Comirnaty sales anticipated to be back-weighted towards the end of the year.
• LOE Headwinds: Pfizer faces significant LOE challenges, with an estimated $14 billion to $15 billion in annual revenue at risk by 2030.
• Market Competition: The company is navigating a competitive landscape in both vaccines and therapeutics, particularly in the obesity and oncology markets.

5. Notable Q&A Insights

• M&A Strategy: Albert Bourla indicated that while Pfizer is open to M&A opportunities, there is currently no plan for a transformative deal, focusing instead on executing AI transformations.
• Oncology Pipeline: Questions about pivotal readouts for SV and Mevro were addressed, with confidence expressed in their potential impact on future growth.
• Vaccination Rates: Discussions highlighted stable vaccination rates in Europe and the U.S., with ongoing efforts to engage governments for continued vaccination campaigns.
• Growth Drivers: Insights into key products expected to drive growth in 2029 included Padcev, Nurtec, and the Metsera obesity portfolio, with confidence in existing franchises and new product launches.

Overall, Pfizer's Q1 2026 results reflect strong operational execution and strategic positioning for future growth, despite facing challenges from competitive pressures and upcoming LOEs.